NASDAQ · BIOA
BioAge Labs, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BIOA: Nov 5, 2026
BioAge Labs, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.68. The reported EPS for the same quarter last year was $-0.56.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.68 | $-0.52 | $-0.87 | 5 |
| Dec 2026 | $-0.70 | $-0.52 | $-0.92 | 5 |
| Mar 2027 | $-0.66 | $-0.66 | $-0.66 | 1 |
| Jun 2027 | $-0.65 | $-0.65 | $-0.65 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · BNK Invest · MarketBeat- Zacks · Oct 29, 9:00 AM EDTEarnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to DeclineBioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Sep 8, 8:27 AM EDTBioAge Labs Initiates Phase 2 QUELL-DME Trial Of BGE-102 In Diabetic Macular Edema(RTTNews) – BioAge Labs, Inc. (BIOA) announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102 in adults with diabetic macular edema (DME).
- RTTNews · Aug 6, 4:29 AM EDTBioAge Labs Q2 NetLoss Expands; Expects QUELL-CV Phase 2 Results Of BGE-102 In H2 2026(RTTNews) – BioAge Labs, Inc. (BIOA), a clinical-stage biopharmaceutical company, reported second-quarter financial results reflecting a wider net loss despite a marginal increase in collaboration-based revenue.
- Zacks · Aug 5, 8:35 PM EDTBioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue EstimatesBioAge Labs, Inc. (BIOA) delivered earnings and revenue surprises of +10.77% and +172.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- BNK Invest · Jul 31, 4:22 PM EDTNoteworthy Friday Option Activity: SIRI, RBLX, BIOAAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in SiriusXM Holdings Inc (Symbol: SIRI), where a total of 74,698 contracts have traded so far, representing approximately 7.5 million underlying shares. That amounts to abo
- MarketBeat · Jun 6, 8:04 AM EDTBioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye DiseaseBioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema. The company’s ch
- Fintel · May 27, 5:14 PM EDTRoth Capital Initiates Coverage of BioAge Labs (BIOA) with Buy RecommendationFintel reports that on May 27, 2026, Roth Capital initiated coverage of BioAge Labs (NasdaqGS:BIOA) with a Buy recommendation. Analyst Price Forecast Suggests 180.19% Upside
- Fintel · May 13, 11:57 AM EDTBTIG Initiates Coverage of BioAge Labs (BIOA) with Buy RecommendationFintel reports that on May 13, 2026, BTIG initiated coverage of BioAge Labs (NasdaqGS:BIOA) with a Buy recommendation. Analyst Price Forecast Suggests 149.53% Upside
- MarketBeat · May 8, 3:12 PM EDTBioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC TrialsBioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across cardiovascular and retinal disease. Management highlighted phase I clinical resul
- BNK Invest · May 6, 3:46 PM EDTNotable Wednesday Option Activity: HUT, BIOA, NVAXAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Hut 8 Corp (Symbol: HUT), where a total of 71,516 contracts have traded so far, representing approximately 7.2 million underlying shares. That amounts to about 148.6% of
- Zacks · Apr 23, 9:40 AM EDTHas Amarin (AMRN) Outpaced Other Medical Stocks This Year?Here is how Amarin (AMRN) and BioAge Labs, Inc. (BIOA) have performed compared to their sector so far this year.
- Zacks · Apr 21, 9:55 AM EDTWall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should KnowThe mean of analysts' price targets for BioAge Labs, Inc. (BIOA) points to an 183.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for BioAge Labs, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.